From your first message to your safe return home — we handle everything, step by step.
HealBridge connects international patients with leading oncology centers in Türkiye offering advanced CAR T-Cell therapy, one of the most innovative forms of cancer immunotherapy.
CAR T-Cell therapy is a breakthrough treatment designed to help the body's immune system recognize and destroy cancer cells more effectively. Through specialized laboratories and highly trained oncology teams, patients may access this cutting-edge therapy as part of modern hematologic cancer treatment programs.
HealBridge coordinates the entire treatment pathway, including medical evaluation, treatment planning, cell processing, therapy administration, and long-term follow-up care.
CAR T-Cell Therapy is an advanced form of immunotherapy that uses the patient's own immune cells to fight cancer.
T-cells are a critical component of the immune system responsible for identifying and destroying abnormal cells. In CAR T-Cell therapy, these immune cells are genetically modified in a laboratory to recognize specific markers on cancer cells.
Once modified, the cells become Chimeric Antigen Receptor T-cells (CAR T-cells) capable of targeting and attacking cancer cells more effectively.
This innovative treatment has shown promising results in certain blood cancers where other treatments may not have been successful.
The process of CAR T-Cell immunotherapy involves several stages.
The patient's T-cells are collected from the blood through a procedure similar to blood donation. This process usually takes several hours.
In specialized laboratories, the T-cells are modified to include chimeric antigen receptors (CARs) that allow them to recognize cancer cells.
The modified T-cells are multiplied in the laboratory to create a large number of therapeutic cells.
Before CAR T-cells are infused back into the body, patients may receive a short course of chemotherapy to prepare the immune system.
The modified immune cells are infused into the patient through an intravenous line. Once inside the body, they begin identifying and attacking cancer cells.
Currently, CAR T-Cell therapy is primarily used for certain types of hematologic cancers.
Approved indications may include:
Many CAR T therapies target specific cancer markers such as CD-19, which is found on certain B-cell cancers.
Research and clinical trials continue to explore the use of CAR T-Cell therapy for additional cancer types.
Not every patient is suitable for CAR T treatment. Eligibility depends on several factors including:
Before treatment, oncologists carefully evaluate each patient to determine whether CAR T immunotherapy is an appropriate option.
In some cases, patients may receive chemotherapy or radiotherapy prior to CAR T therapy to reduce disease burden.
The entire CAR T-Cell therapy process usually takes several weeks from cell collection to infusion.
Blood cells are collected through a procedure called leukapheresis, which typically takes 2–4 hours.
The collected T-cells are modified in a laboratory to recognize cancer cells. This process can take several weeks.
Patients may receive several days of chemotherapy to prepare the immune system for CAR T-cell infusion.
The engineered cells are infused back into the patient through an intravenous line. The infusion itself usually takes less than one hour.
Once inside the body, the modified immune cells begin targeting cancer cells.
Patients receiving CAR T-Cell therapy require close monitoring after treatment.
The first weeks following infusion are critical for observing the body's response and managing potential side effects.
Patients may remain under medical observation for a period following treatment, depending on their condition.
Monitoring may include:
Long-term follow-up is essential to assess treatment response and maintain patient safety.
Clinical studies have demonstrated promising results for CAR T-Cell therapy in several blood cancers, particularly in patients whose disease has not responded to conventional treatments.
For some patients with acute lymphoblastic leukemia or certain lymphomas, CAR T therapy may lead to long-term remission.
Outcomes vary depending on factors such as:
Research in cancer immunotherapy continues to expand the potential of CAR T-cell treatment across additional cancer types.
HealBridge connects patients with specialized oncology centers in Türkiye offering advanced CAR T-Cell immunotherapy programs and modern hematologic cancer treatment.
Patients benefit from:
Our goal is to help patients access innovative cancer treatments such as CAR T-Cell therapy in Türkiye while ensuring expert care, clear communication, and continuous support throughout the treatment journey.